RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections Clinical Trial

Official title:

A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400μg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01230645
• Other study ID #: RVH003
• Secondary ID: 2010-021527-26
• Status: Completed
• Phase: Phase 1
• First received: October 27, 2010
• Last updated: February 10, 2011
• Start date: October 2010
• Est. completion date: January 2011

Study information

• Verified date: February 2011
• Source: Respivert Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 is effective in reducing the inflammation caused by viral infections such as RSV (respiratory syncytial virus).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: January 2011
• Est. primary completion date: December 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• healthy male subjects aged 18 - 45 years

• agreeable to use adequate contraception throughout the study

• negative hepatitis B, hepatitis C and HIV screen

• negative drugs of abuse, alcohol and nicotine screen

• able to provide written informed consent and be willing to comply with the study restrictions and requirements

• low titres of RSV neutralising antibody measured during screening

Exclusion Criteria:

• acute or chronic illness or clinically relevant abnormality noted at the screening visit

• presence of febrile illness or symptoms of upper or lower respiratory tract infection in the 28 days prior to viral inoculation

• history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition

• diabetes

• history or evidence of autoimmune disease or known impaired immune responsiveness

• recent (within the last 3 years) and/or recurrent history of autonomic dysfunction

• anatomic or neurological abnormality impairing the gag reflex or associated with an increased risk of aspiration, any abnormality significantly altering the anatomy of the nose or nasopharynx. Known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome. Any nasal or sinus surgery within 4 months prior to virus administration.

• history of smoking in the past 6 months

• positive test for drugs or alcohol at screening

• inadequate venous access

• abnormal pulmonary function at screening

• abnormal laboratory or ECG at screening

• acute or chronic use of medication to treat nasal congestion

• use of any prescription drugs, herbal supplements, within 4 weeks prior to virus challenge, and/or over-the-counter medication, dietary supplements within 2 weeks prior to virus challenge

• treatment with systemic glucocorticoids, antiviral drugs, immunoglobulins or blood transfusions within 1 month, or any other cytotoxic or immunosuppressive drug within 6 months prior to dosing. Receipt of any systemic chemotherapy agent at any time

• treatment with any investigational drug within 3 months, or prior participation in a clinical trial of any RSV IMP, medication or experimental RSV viral challenge delivered directly to the respiratory tract within 1 year prior to dosing, or receipt of more than 4 investigational drug within 12 months

• history of multiple and recurring allergies and/or adverse reaction to any components of the challenge virus preparation

• allergy to gentamicin

• significant history of seasonal hay fever or seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or chronic nasal or sinus condition

• intention to travel between first and last visit (to countries for which vaccinations are recommended or where high risk of infection exists)

• healthcare workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of viral challenge

• household member or close contact (for an additional 2 weeks after discharge from the isolation facility) who is:

1. less than 3 years of age;

2. any person with any known immunodeficiency;

3. any person receiving immunosuppressant medications;

4. any person undergoing or soon to undergo cancer chemotherapy within 28 days of viral challenge;

5. any person who has diagnosed emphysema or COPD, is elderly residing in a nursing home, or with severe lung disease or medical condition including but not exclusive to the conditions listed below; or

6. any person who has received a transplant (bone marrow or solid organ)

• employees or relatives of Retroscreen Virology or RespiVert Ltd

• other finding in the medical interview, physical exam, or screening investigations that, in the opinion of the Investigator, deem the subject unsuitable for the study

• subjects who in the opinion of their general practitioner or the Investigator, should not participate in the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Respiratory Syncytial Virus Infections
• Virus Diseases

Intervention

Drug:
• RV568
RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
• Placebo
Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)

Locations

Country	Name	City	State
United Kingdom	Retroscreen Virology Ltd	London

Sponsors (1)

Lead Sponsor	Collaborator
Respivert Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IL8 induction in nasal wash samples		16 day quarantine period	No
Secondary	RSV viral load		16 day quarantine period	No
Secondary	Changes in symptoms of RSV infection		16 day quarantine period	No
Secondary	Assessment of mucus weight and tissue counts		16 day quarantine period	No
Secondary	Viable nasal cell counts in nasal washes		16 day quarantine period	No
Secondary	Frequency of RSV infection		16 day quarantine period	No
Secondary	Plasma RV568 levels		16 day quarantine period	No
Secondary	Assessment of IL6 in nasal wash samples		16 day quarantine period	No